Here, we showed that therapeutic inhibition of IL-6R with tocilizumab has no measurable effect on mucoepidermoid carcinoma cell viability, cell cycle, or sphere formation in vitro. The gene discussed is IL6R; the disease is mucoepidermoid carcinoma.